AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00214422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
Study NCT03709927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01
Description: 6g IV fosfomycin
Study NCT03709927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
Study NCT03709927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: IV Placebo (0.9% Normal Saline)
Study NCT03709927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IV
Description: IV Placebo (0.9% Normal Saline)
Study NCT03896295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion
Study NCT03352531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK-105
Description: Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
Study NCT02039739 — intervention group
Intervention type: DEVICE
Intervention: Orsiro™ Drug Eluting Stent group
Study NCT02424266 — intervention group
Intervention type: DEVICE
Intervention: None invasive imaging of the tear film (AdOM)
Description: White light tomography imaging
Study NCT02126137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study NCT03047317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MABp1
Description: Single dose of intravenous MABp1
Study NCT02605928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injeq Bioimpedance Probe (BIP) Needle
Description: Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
Study NCT03141840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABL01
Description: Experimental medical device
Study NCT03141840 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ABL01 lacking active component
Study NCT05057650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Provide
Study NCT01592578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligation and Cyanoacrylate
Description: Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
Study NCT01592578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation plus Sclerotherapy and Cyanoacrylate Group
Description: Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
Study NCT00552669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sirolimus
Description: Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
Study NCT00552669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting stent
Description: Any Drug eluting stent
Study NCT06366477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration stimulation combined with task-oriented training
Description: Participants with chronic stroke underwent 24 sessions of vibration stimulation combined with task-oriented training over 12 weeks, in addition to regular therapy.
Study NCT03922906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
Study NCT01513434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transtibial technique
Description: Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
Study NCT01513434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transportal technique
Description: Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
Study NCT01513434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
Study NCT00660426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00660426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00660426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02160210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafine Endoscope
Description: Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
Study NCT01894672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study NCT04127201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: en_línea
Description: This is an online adaptation of the LEARN program. A self-help weight control program developed by Kelly Brownell in 2004.
Study NCT04127201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: This is a traditional behavioral weight control program
Study NCT00582894 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfex, Fludarabine, ALemtuzumab
Description: Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
Study NCT03416231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
Study NCT03416231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
Study NCT04029857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement Drink
Description: Given standard of care nutritional supplementation
Study NCT04029857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given Impact Advanced Recovery PO or via feeding tube
Study NCT02730260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nondirective smoking cessation coaching
Description: Quitline coach allows participant to set agenda for each call.
Study NCT02730260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directive smoking cessation coaching
Description: Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
Study NCT03635931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor
Description: surgical treatment with CGF for papilla regeneration
Study NCT02771834 — intervention group
Intervention type: OTHER
Intervention: Biomechanical analysis
Study NCT02771834 — intervention group
Intervention type: OTHER
Intervention: Kiphosis analysis
Study NCT01876875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy-restricted, n-3 polysaturated fatty acids-rich diet
Description: The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
Study NCT02771834 — intervention group
Intervention type: OTHER
Intervention: Vitamin D level
Study NCT02305563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564
Study NCT02305563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BMS-936564
Study NCT02305563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02305563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Study NCT00054132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00054132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00054132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01290887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
Study NCT00823641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
Study NCT01876875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: The patients of this group were randomized to continue their usual diet
Study NCT01428947 — intervention group
Intervention type: PROCEDURE
Intervention: Arterial approach
Description: Randomization to right radial or femoral approach
Study NCT02653703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical L-menthol 40%
Description: Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
Study NCT02653703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle, topical ethanol 96%
Description: Organic solvent CAS Number: 64-17-5
Study NCT04399460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy-based commercially available food products
Description: Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
Study NCT04399460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive Eating
Description: Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
Study NCT02793648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
Study NCT02793648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
Study NCT02793648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
Study NCT00881088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: nadroparin 0,3 cc once daily during immobilization period
Study NCT00881088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: Fondaparinux 2,5 mg daily during immobilization period
Study NCT01641380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: 1. Online enrollment in the Compliance for Life® (CFL) system through iReminder)~2. Welcome Message 24 hrs after enrollment~3. Appointment Reminder prior to 3 month injection cycles~4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)
Study NCT03123471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablets BID from weeks 0 to 32.
Study NCT03123471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
Study NCT03862508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model).
Study NCT05367375 — intervention group
Intervention type: PROCEDURE
Intervention: removing osteophyte at patellofemoral joint
Description: to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
Study NCT02977182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy (CDT)
Description: CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
Study NCT01525992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community pharmacist-led diabetes education program
Description: A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
Study NCT02707185 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simulation-Based Training
Description: An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
Study NCT00834015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial
Description: combined strength and aerobic training group
Study NCT03835091 — intervention group
Intervention type: OTHER
Intervention: BRASS score
Description: Brainstem response on neurologic examination
Study NCT04573101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf
Study NCT03123471 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
Study NCT01967485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text- Messaging
Description: Text messages will be sent to the parents of children enrolled in the study.
Study NCT01967485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Children will receive stimulant treatment for ADHD.
Study NCT01967485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Children will receive stimulant treatment for ADHD.
Study NCT03661593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cataract guideline
Description: The patients gets an IOL according to cataract guideline correcting the ametropia
Study NCT00095212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 Transdermal Testosterone (Patch)
Description: 300 micrograms twice a week
Study NCT00095212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 Placebo Patch
Description: Placebo patch (0 micrograms of testosterone) applied twice a week
Study NCT04836078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap subgingival debridement
Description: After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
Study NCT04836078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap subgingival debridement
Description: After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
Study NCT04836078 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: open flap subgingival debridement
Description: After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
Study NCT04836078 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subgingival injection of chitosan 2% gel
Description: Group (I); injected subgingivally with chitosan 2% gel containing a microsponges formulated drug weekly
Study NCT04836078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival injection of chitosan 2% gel
Description: Group (II); injected subgingivally with chitosan 2% gel containing free drug weekly
Study NCT04836078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival injection of chitosan 2% gel
Description: Group (III); injected subgingivally with placebo chitosan 2% gel weekly
Study NCT01705015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct feedback about exercise
Study NCT02870920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT02870920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT02870920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Study NCT02870920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Study NCT02071875 — intervention group
Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM recording
Description: Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
Study NCT03687736 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AbobotulinumtoxinA
Description: AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
Study NCT02841488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous peripheral sciatic nerve block
Description: Continuous infusion of local anesthetics through perineural sciatic nerve catheter
Study NCT01525992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
Study NCT01715597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
Study NCT01715597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline 500ml IV
Study NCT01715597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: normal saline 500ml IV